SBIR PHASE I--MEDICATIONS DEVELOPMEN-DEPOT NALMEFENE

SBIR I 期药物开发-DEPOT Nalmefene

• 批准号: 2835274
• 负责人: ELIE NUWAYSER
• 金额: $ 10万
• 依托单位: BIOTEK, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-06 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2835274
• 关键词: analog; dosage forms; drug design /synthesis /production; drug screening /evaluation; microcapsule; naltrexone; slow release drug

The primary objective of this SBIR Phase I contract is to optimize the properties of the 30-day nalmefene microcapsule formulation but utilizing a microsphere core instead of a spray core; to characterize ifs physical, chemical, and in vivo performance properties; and to finalize the process of manufacture in preparation for cGMP production during Phase II.

SBIR 第一阶段合同的主要目标是优化 30 天纳美芬微胶囊制剂的特性，但利用 微球芯代替喷雾芯；来表征 ifs 的物理特征， 化学和体内性能特性；并完成该过程 为第二阶段的 cGMP 生产做准备。